Oral hydrogen water prevents chronic allograft nephropathy in rats.
Jon S Cardinal, Jianghua Zhan, Yinna Wang, Ryujiro Sugimoto, Allan Tsung, Kenneth R McCurry, Timothy R Billiar, Atsunori Nakao · Kidney international · 2010
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In contrast, treatment with HW improved allograft function, slowed the progression of CAN, reduced oxidant injury and inflammatory mediator production, and improved overall survival. These results are preclinical and suggest molecular hydrogen's therapeutic potential in the condition studied. Further human research is needed to establish clinical effectiveness.
What the Researchers Studied
The study examined rats.
How Molecular Hydrogen Was Used
Molecular hydrogen was dissolved in water and recipients were given HW from day 0 until day 150.
What the Researchers Found
In contrast, treatment with HW improved allograft function, slowed the progression of CAN, reduced oxidant injury and inflammatory mediator production, and improved overall survival. Hence, oral HW is an effective antioxidant and antiinflammatory agent that prevented CAN, improved survival of rat renal allografts, and may be of therapeutic value in the setting of transplantation.
H₂ Mechanisms / Biological Findings
The source material reviewed did not establish a specific molecular hydrogen mechanism for the reported findings.
Authors’ Conclusion
A distinct authors’ conclusion was not available in the source material reviewed by H2HUBB.